Calvin H. Knowlton Sells 8,000 Shares of Tabula Rasa HealthCare Inc (TRHC) Stock

Share on StockTwits

Tabula Rasa HealthCare Inc (NASDAQ:TRHC) CEO Calvin H. Knowlton sold 8,000 shares of Tabula Rasa HealthCare stock in a transaction that occurred on Monday, October 8th. The shares were sold at an average price of $74.22, for a total transaction of $593,760.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

NASDAQ TRHC opened at $74.38 on Friday. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of -1,859.50, a P/E/G ratio of 6.13 and a beta of 2.85. Tabula Rasa HealthCare Inc has a fifty-two week low of $24.24 and a fifty-two week high of $91.16. The company has a current ratio of 0.36, a quick ratio of 0.33 and a debt-to-equity ratio of 0.11.

Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its earnings results on Tuesday, August 7th. The company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.12. The firm had revenue of $48.60 million for the quarter, compared to analysts’ expectations of $46.73 million. Tabula Rasa HealthCare had a negative net margin of 16.78% and a positive return on equity of 4.55%. As a group, sell-side analysts predict that Tabula Rasa HealthCare Inc will post 0.53 earnings per share for the current year.

TRHC has been the topic of a number of recent analyst reports. Citigroup lifted their price objective on shares of Tabula Rasa HealthCare to $100.00 and gave the company a “buy” rating in a research note on Thursday. Zacks Investment Research raised shares of Tabula Rasa HealthCare from a “hold” rating to a “buy” rating and set a $74.00 price objective on the stock in a research note on Saturday, August 11th. Robert W. Baird reissued a “buy” rating and issued a $70.00 price objective on shares of Tabula Rasa HealthCare in a research note on Wednesday, August 8th. BidaskClub cut shares of Tabula Rasa HealthCare from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 15th. Finally, Stifel Nicolaus initiated coverage on shares of Tabula Rasa HealthCare in a research note on Tuesday, September 11th. They issued a “hold” rating and a $95.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $71.75.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. grew its stake in shares of Tabula Rasa HealthCare by 29.7% during the second quarter. BlackRock Inc. now owns 2,119,507 shares of the company’s stock worth $135,288,000 after buying an additional 484,979 shares during the last quarter. Jennison Associates LLC grew its stake in shares of Tabula Rasa HealthCare by 29.5% during the second quarter. Jennison Associates LLC now owns 757,846 shares of the company’s stock worth $48,373,000 after buying an additional 172,693 shares during the last quarter. NN Investment Partners Holdings N.V. bought a new stake in shares of Tabula Rasa HealthCare during the second quarter worth $29,439,000. Braun Stacey Associates Inc. grew its stake in shares of Tabula Rasa HealthCare by 199.0% during the second quarter. Braun Stacey Associates Inc. now owns 301,089 shares of the company’s stock worth $19,219,000 after buying an additional 200,394 shares during the last quarter. Finally, Northern Trust Corp grew its stake in shares of Tabula Rasa HealthCare by 52.3% during the second quarter. Northern Trust Corp now owns 227,503 shares of the company’s stock worth $14,522,000 after buying an additional 78,112 shares during the last quarter. 75.15% of the stock is currently owned by hedge funds and other institutional investors.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.

Featured Story: Leveraged Buyout (LBO)

Insider Buying and Selling by Quarter for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply